Last updated: June 4, 2026
Carbidopa and levodopa are widely supplied because the combination is mature and has multiple approved sources in immediate-release and extended-release tablet formats. The supply chain splits into (1) active pharmaceutical ingredient (API) manufacturers and (2) finished-dosage manufacturers that hold Abbreviated New Drug Application (ANDA) approvals or market branded products in the US.
Which companies supply carbidopa and levodopa APIs for generic and branded products?
Answer: The API supply base for carbidopa and levodopa is broad, spanning multiple Indian, Chinese, and European chemical/pharma manufacturers. However, supplier lists depend on the dosage form (immediate-release vs extended-release), the salt/form used, and whether the target is US FDA approval, export-only supply, or internal captive manufacture.
API supply chain patterns
- Levodopa is typically produced via chemical synthesis (multi-step routes) with downstream purification and crystallization controls to meet impurity and polymorph specs.
- Carbidopa is produced as a separate API, then combined with levodopa at the finished-dosage stage or as part of a co-processed input stream where applicable.
What to expect from supplier qualification
Most finished-dosage suppliers source APIs through either:
- Qualified supplier frameworks tied to FDA filings and DMFs, or
- Direct captive synthesis for one API with outsourced sourcing for the other.
API/DMF-driven sourcing is the practical supplier filter
For regulated supply, the “real” supplier universe is the set of firms with active DMFs (Drug Master Files) supporting US approvals. Many generic and branded product approvals cite one or more DMF holders for carbidopa and levodopa.
What finished-dose manufacturers supply carbidopa and levodopa tablets in the US?
Answer: US supply is split across branded holders and multiple ANDA manufacturers. The practical way to enumerate the supplier set is to map:
- FDA approval (ANDA vs NDA),
- dosage strength, and
- release profile (immediate-release vs extended-release).
How the supplier set differs by formulation
- Immediate-release (IR) carbidopa/levodopa tablets are typically supplied through multiple ANDAs plus branded product availability.
- Extended-release (ER) formulations (notably carbidopa/levodopa ER) usually have fewer ANDA competitors than IR, since ER technology and dissolution specs can narrow qualified manufacturing paths.
Key commercial implication
If a buyer needs supply for ER, supplier counts are materially lower than for IR, and lead times can diverge.
What patents protect carbidopa/levodopa formulations and how does that affect supplier access?
Answer: The active ingredients are long off patent in most jurisdictions, so formulation and method patents govern many incremental variants. For suppliers, the effect is mostly about:
- Whether a firm can commercialize a specific release profile without infringement,
- Whether it can launch an ANDA with paragraph IV or “carve-out” design changes.
Typical IP zones that can restrict manufacturing
- Polymorph control and crystallization processes for API intermediates
- Formulation dissolution profiles and excipient systems
- ER matrix technologies and coating processes
Supply consequence
When IP barriers are weak for the core IR tablet category, suppliers expand. When ER-specific patents exist (even if limited), fewer suppliers can qualify.
What is the Orange Book status of US carbidopa/levodopa products?
Answer: Carbidopa and levodopa are represented by multiple US approvals with listed patents in the Orange Book for specific products and strengths. Orange Book status is product-specific: different strengths and release profiles can have different listed patents and expiration dates.
How to translate Orange Book into supplier reality
- If a product’s listed patents are expired, more ANDA suppliers can enter without IP-driven design constraints.
- If listed patents remain, ANDA applicants must align with design and certification strategy.
When do carbidopa and levodopa products lose exclusivity or key listed-patent coverage?
Answer: For most existing carbidopa/levodopa presentations, active ingredient exclusivity has expired. Remaining constraints usually track listed patents on specific formulation or method claims rather than new regulatory exclusivities.
Timing risk is formulation-specific
- IR: often fewer remaining patent barriers; more supply options.
- ER: risk profile depends on whether formulation-specific patents remain listed and whether generic designs are “equivalent” on dissolution and release.
Are Paragraph IV challenges common for carbidopa and levodopa generics?
Answer: Paragraph IV filing activity is generally lower for mature IR combinations where multiple ANDAs already exist, but it can occur for constrained formats such as ER products if formulation patents or method patents still apply.
How does biosimilar risk apply to carbidopa and levodopa?
Answer: No biosimilar risk. Carbidopa and levodopa are small-molecule drugs, not biologics.
Which suppliers compete in immediate-release vs extended-release carbidopa/levodopa?
Answer: IR typically has a larger competitor set than ER. The supplier landscape for ER tends to concentrate among companies with established tablet ER platforms and demonstrated dissolution robustness.
Procurement implication
- For IR: sourcing is usually less constrained.
- For ER: qualification and manufacturing capacity can be a gating factor.
What manufacturing/IP barriers can limit supply for carbidopa/levodopa?
Answer: The barriers that matter in practice are:
- Release-profile and dissolution equivalency for ER,
- Impurity controls for APIs (including residual solvents, degradation products, and heavy metals),
- Process validation and scale-up reproducibility for finished tablets.
API-quality drivers
- Particle size and polymorphic form controls for levodopa can affect dissolution.
- Carbidopa impurity profiles can affect tablet stability and regulatory acceptance.
Key procurement checklist for buyers identifying suppliers
Even where multiple suppliers exist, qualification filters reduce the field:
- Regulatory alignment: FDA-approved DMFs where needed, or documented pathway compliance for ANDA/market supply.
- Dosage-form match: IR vs ER, and exact strength.
- Impurity and specification fit: levodopa impurity limits, carbidopa assay/impurities, dissolution specs.
- Capacity and lead time: especially for ER.
- Batch traceability: CoA reliability and change-control history.
Table: Supplier landscape segmentation (practical view)
| Segment |
What it supplies |
Typical buyer use |
Supplier concentration |
| API (carbidopa) |
Carbidopa API |
Custom finished-dose build, blending, internal tablet manufacturing |
Many global chemical/pharma suppliers |
| API (levodopa) |
Levodopa API |
Tablet manufacture, internal API blending |
Many global chemical/pharma suppliers |
| Finished-dose IR tablets |
Carbidopa/levodopa IR |
US market supply, hospital contracts |
Broad; many ANDA sources |
| Finished-dose ER tablets |
Carbidopa/levodopa ER |
US market supply; preference for dosing convenience |
Narrower; more tech-specific entrants |
Key Takeaways
- Carbidopa/levodopa supply is widely available because both actives are mature, with multiple US ANDA and international suppliers.
- Supplier lists that matter operationally are defined by (1) API DMF holders and (2) FDA-approved finished-dose manufacturers matched to IR vs ER.
- The main constraint is not biosimilar regulation, but formulation-specific equivalency requirements and release-profile IP for ER products.
FAQs
1) Which category of suppliers matters more for carbidopa/levodopa procurement: API or finished-dose manufacturers?
Finished-dose manufacturers matter most for direct market supply; API suppliers matter for contract manufacturing or in-house formulation.
2) Do extended-release carbidopa/levodopa have fewer generic suppliers than immediate-release?
Yes, ER generally has fewer qualified competitors due to tighter dissolution and release-profile requirements.
3) What quality specs most affect levodopa acceptance across suppliers?
Assay, impurity profile, and dissolution-relevant characteristics such as solid-state behavior.
4) Can one finished-dose supplier source both actives from the same API manufacturer?
Often not; carbidopa and levodopa are commonly sourced from different API suppliers even when both are supplied to the same tablet manufacturer.
5) What regulatory system governs small-molecule supply for carbidopa/levodopa in the US?
ANDA approvals and the Orange Book patent listings for each specific product, plus DMF-supported API controls where applicable.
